Stocks rise 65.9% post-IPO for newly public biotech companies
This article was originally published in Scrip
Biotechnology investment bubble or not, the average return on investment for 29 drug developers that launched initial public offerings during the first nine months of the year is 65.9%. That's a compelling figure for companies trying to decide if they should go public in 2013 and for investors considering whether to participate in biotech IPOs.
You may also be interested in...
Private Company Edition: Venture capital invested in pharma and biotech in 2020 totaled $19.5m through Q3, just $400m below the full-year record total of $19.9bn in 2018. Also, Canaan and Catalio reveal new VC funds, while Talaris’s $115m series B leads recent financings.
Biopharma executives discussed their strategies for treating chronic diseases during the Cell and Gene Meeting on the Mesa, including R&D and regulatory considerations.
Bristol Myers Squibb reported detailed results from the Phase III TRUE NORTH study that show durable remissions in a patient population that switches therapies due to loss of response.